Table 2.
Primary endpoint of renin–angiotensin–aldosterone system inhibitor treatment categories at 3 months
| (%) of subjects a | Global test of no difference | |||||
|---|---|---|---|---|---|---|
| Group | n | No ACEi/ARB/ARNI or at less than target dose and no MRA | ACEi/ARB/ARNI at target dose and no MRA | MRA at less than target dose b | MRA at target dose b (50 mg daily) | Pooled P value |
| A—Primary analysis in the intent‐to‐treat population | ||||||
| SZC (N = 92) | 89 | 14.7 | 14.7 | 14.2 | 56.4 | 0.43 |
| Placebo (N = 90) | 87 | 13.5 | 15.1 | 24.5 | 47.0 | |
| B—Sensitivity analysis without imputation in the intent‐to‐treat population | ||||||
| SZC (N = 92) | 58 | 8 (13.8) | 9 (15.5) | 4 (6.9) | 37 (63.8) | 0.35 |
| Placebo (N = 90) | 49 | 6 (12.2) | 10 (20.4) | 8 (16.3) | 25 (51.0) | |
| C—Sensitivity analysis with last value carry forward in the intent‐to‐treat population | ||||||
| SZC (N = 92) | 92 | 16 (17.4) | 15 (16.3) | 16 (17.4) | 45 (48.9) | 0.42 |
| Placebo (N = 90) | 90 | 16 (17.8) | 15 (16.7) | 24 (26.7) | 35 (38.9) | |
| D—Sensitivity analysis related to COVID‐19 (prior to 11 March 2020, ITT population) | ||||||
| SZC (N = 92) | 76 | 14.4 | 15.9 | 15.8 | 53.9 | 0.62 |
| Placebo (N = 90) | 81 | 13.3 | 16.3 | 24.9 | 45.6 | |
Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor and neprolysin inhibitors; MRA, mineralocorticoid receptor antagonist; n, number of subjects in analysis.
a
Multiple imputation technique was used to impute missing values at 3 months. Pooled P value was obtained from F distribution with combined results from χ 2 tests on imputed individual data sets. Proportion of subjects in each category was obtained by pooling/averaging the proportion from individual data sets, each calculated using n as denominator.
b
Irrespective of ACEi, ARB, or ARNi dose.